April 8, 2009—Genentech announced that it would recall Raptiva due to risk of a rare and often fatal brain infection. The recall comes on the heels of an FDA warning in February 2009 and follows a recommendation by European regulators to forbid the sale of the drug.
The drug is linked to progressive multifocal leukoncephalopathy (PML). PML is caused by a virus that virtually everyone carries but can attack the brain in those patients whose immune systems are weakened.
Doctors are being instructed not to issue prescriptions to new patients and contact those patients presently taking the drug to discuss alternatives. Raptiva will no longer be available after June 8, 2009.
|